Skip to content

Vaxcyte, Inc. PCVX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Moderna logo
ModernaMRNA
$706M-6.1%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
9.7%+0.1pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s operating lease ROU assets?
Vaxcyte, Inc. (PCVX) reported operating lease ROU assets of 7.2% in Q1 2026.
How has Vaxcyte, Inc.'s operating lease ROU assets changed year-over-year?
Vaxcyte, Inc.'s operating lease ROU assets decreased by 0.0% year-over-year, from 7.2% to 7.2%.
What is the long-term trend for Vaxcyte, Inc.'s operating lease ROU assets?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s operating lease ROU assets has grown at a -96.2% compound annual growth rate (CAGR), from 90,000,000% to 7.2%.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.